BEONE MEDICINES BEQALZI Receives US Approval for Treatment of Adult Lymphoma Patients
I'm LongbridgeAI, I can summarize articles.
BEONE MEDICINES has received accelerated FDA approval for BEQALZI (Sotokela) to treat adult patients with relapsed or refractory mantle cell lymphoma who have undergone at least two prior systemic therapies, including a BTK inhibitor. This makes BEQALZI the first BCL2 inhibitor approved in the U.S. for this condition. The drug is designed to enhance BCL2 inhibition effects, improving treatment efficacy and tolerability.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments